Inflammatory Myofibroblastic Tumor Overview

Save information for later
Sign Up

Learn About Inflammatory Myofibroblastic Tumor

What is the definition of Inflammatory Myofibroblastic Tumor?
An Inflammatory myofibroblastic tumor (IMT) is an uncommon, usually benign (non-cancerous) tumor made up of cells called myofibroblastic spindle cells. It usually develops in children or young adults, but can affect people of any age. An IMT can occur in almost any part of the body but is most commonly found in the lung, orbit (eye socket), peritoneum (lining of the abdominal cavity and internal organs), and mesentery. Signs and symptoms vary depending on the site of the tumor. Some people with an IMT are asymptomatic, while others may have nonspecific respiratory symptoms, fever, or pain. IMTs may recur, and become locally invasive and/or spread (metastasize) to other parts of the body. However, malignant (cancerous) IMTs are rare. The underlying cause of IMTs is poorly understood. Some cases have been linked to translocations involving the ALK gene.
What are the alternative names for Inflammatory Myofibroblastic Tumor?
  • Inflammatory myofibroblastic tumor
  • Inflammatory fibrosarcoma
Who are the top Inflammatory Myofibroblastic Tumor Local Doctors?
Patrick Schoffski
Elite in Inflammatory Myofibroblastic Tumor
Patrick Schoffski
Elite in Inflammatory Myofibroblastic Tumor
Patrick Schoffski
Leuven, VLG, BE 

Patrick Schoffski practices in Leuven, Belgium. Mr. Schoffski is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, Tissue Biopsy, and Nephrectomy.

Elite in Inflammatory Myofibroblastic Tumor
Raf E. Sciot
Elite in Inflammatory Myofibroblastic Tumor
Raf E. Sciot
Leuven, VLG, BE 

Raf Sciot practices in Leuven, Belgium. Sciot is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. Their top areas of expertise are Inflammatory Myofibroblastic Tumor, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Synovial Sarcoma, and Thrombectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Pedro T. Ramirez
Advanced in Inflammatory Myofibroblastic Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology
Advanced in Inflammatory Myofibroblastic Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology

Tmh Physician Associates PLLC

6550 Fannin St, Suite 901, 
Houston, TX 
713-441-1026
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pedro Ramirez is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Ramirez is rated as an Advanced provider by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy. Dr. Ramirez is currently accepting new patients.

View All Doctors
What are the latest Inflammatory Myofibroblastic Tumor Clinical Trials?
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Who is this study for: Pediatric and young adult patients with ALK+ anaplastic large cell lymphoma, inflammatory myofibroblastic tumors or other solid tumors
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 1/Phase 2

Summary: This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Who is this study for: Patients with Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2

Summary: Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center